Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 15/20 | 0.48 |
| ▸ | ICAM1 | P05362 | 15/20 | 0.48 |
| ▸ | ITGAL | P20701 | 15/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150948 | 0.98 | ITGB2 (0.48) | ITGB2ICAM1ITGALHSD11B1 | |
| SCHEMBL7144912 | 0.92 | ITGB2 (0.46) | ITGB2ICAM1ITGAL | |
| SCHEMBL7141584 | 0.88 | ITGAL (0.63) | ITGB2ICAM1ITGALHSD11B1 | |
| SCHEMBL7144908 | 0.86 | ITGB2 (0.44) | ITGB2ICAM1ITGAL | |
| SCHEMBL7141569 | 0.82 | ITGB2 (0.64) | ITGB2ICAM1ITGALHSD11B1 | |
| SCHEMBL7146696 | 0.80 | ITGB2 (0.46) | ITGB2ICAM1ITGAL | |
| SCHEMBL7146698 | 0.76 | ITGB2 (0.60) | ITGB2ICAM1ITGAL | |
| SCHEMBL7147403 | 0.76 | ITGB2 (0.50) | ITGB2ICAM1ITGAL | |
| SCHEMBL7147405 | 0.74 | ITGB2 (0.61) | ITGB2ICAM1ITGAL | |
| SCHEMBL7166029 | 0.72 | ITGAL (0.49) | ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6521619-B2 | Bind to the interaction-domain of integrin lfa-1 interrupting enothelial cell-leukocyte adhesion | ICOS CORPORATION | 2003-02-18 | — | — | US | claimed |
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICOS CORPORATION | 2002-10-24 | — | — | US | claimed |
| US-6521619-B2 | Bind to the interaction-domain of integrin lfa-1 interrupting enothelial cell-leukocyte adhesion | ICOS CORPORATION | 2003-02-18 | — | — | US | disclosed |
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICOS CORPORATION | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156314-A1 | Aryl phenylcyclopropyl sulfide derivatives and their use as cell adhesion inhibiting anti-inflammatory and immune suppressive agents | ICAM1, VCAM1, CD47 | ITGB2 120/4885ICAM1 1/4885ITGAL 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.